This presentation contains
forward-looking statements, including, but not limited to, statements regarding our
expectations and projections regarding our future operating results and financial
performance, anticipated cost or expense reductions, plans with respect to
commercializing our product and product candidates, our translational research program,
expectations regarding our manufacturing capabilities, the expected timing of release of
additional data for our product candidates, plans to initiate additional studies for product
candidates and timing and design of these studies, plans regarding ongoing studies for
existing programs, our liquidity position as of the most recent fiscal quarter end,
expectations regarding the adequacy of clinical data to support marketing applications and
approvals of product candidates, our intent to file, and potential timing and success of,
marketing applications and other regulatory approvals, expectations regarding timing of
receiving potential approval of product candidates, expectations regarding prevalence of
patients, future regulatory interactions, and the value to be generated by our pipeline.